About
Technology
Issues
FAQ
Links
Official Page
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.